PCVX on Nasdaq
Vaxcyte, Inc.
American biological products company based in San Carlos, active since 2013.
Price unavailable
Last updated Oct 18, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development | $794.3M | $476.6M | $332.3M |
| Acquired manufacturing rights | $0 | $0 | $75.0M |
| General and administrative | $129.4M | $92.9M | $60.7M |
| Total operating expenses | $923.7M | $569.5M | $468.0M |
| Loss from operations | -$923.7M | -$569.5M | -$468.0M |
| Interest income | $119.7M | $110.0M | $62.9M |
| Other income (expense) | $37.3M | -$4.4M | $2.9M |
| Total other income, net | $157.0M | $105.6M | $65.8M |
| Net loss | -$766.6M | -$463.9M | -$402.3M |
| Net loss per share, basic (in dollars per share) | -$5.63 | -$3.80 | -$4.14 |
| Net loss per share, diluted (in dollars per share) | -$5.63 | -$3.80 | -$4.14 |
| Weighted-average shares outstanding, basic (in shares) | 136.1M shares | 122.0M shares | 97.2M shares |
| Weighted-average shares outstanding, diluted (in shares) | 136.1M shares | 122.0M shares | 97.2M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $174.0M | $387.9M | $397.5M | |
| Short-term investments | $1.4B | $1.4B | ||
| Prepaid expenses and other current assets | $66.4M | $40.8M | ||
| Total current assets | $1.6B | $1.8B | ||
| Property and equipment, net | $257.4M | $198.0M | ||
| Operating lease right-of-use assets | $116.0M | $72.1M | ||
| Long-term investments | $881.7M | $1.4B | ||
| Restricted cash | $1.5M | $1.3M | ||
| Other assets | $118.8M | $64.4M | ||
| Total noncurrent assets | $1.4B | $1.7B | ||
| Total assets | $3.0B | $3.5B | ||
| Accounts payable | $70.9M | $48.5M | ||
| Accrued compensation | $23.0M | $20.6M | ||
| Accrued contract manufacturing expenses | $74.7M | $36.2M | ||
| Accrued expenses | $31.1M | $29.1M | ||
| Operating lease liabilities current | $6.1M | $5.9M | ||
| Total current liabilities | $205.8M | $140.2M | ||
| Operating lease liabilities long-term | $111.4M | $65.2M | ||
| Other liabilities | $100.0K | $100.0K | ||
| Total liabilities | $317.2M | $205.5M | ||
| Preferred stock, $0.001 par value 10,000,000 authorized at December 31, 2025 and December 31, 2024; no shares issued and outstanding at December 31, 2025 and December 31, 2024 | $0 | $0 | ||
| Common stock, $0.001 par value 500,000,000 shares authorized at December 31, 2025 and December 31, 2024; 131,058,858 and 124,893,034 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $134.0K | $128.0K | ||
| Additional paid-in capital | $4.8B | $4.7B | ||
| Accumulated other comprehensive income (loss) | $1.6M | -$3.9M | ||
| Accumulated deficit | -$2.2B | -$1.4B | ||
| Total stockholders' equity | $2.7B | $3.3B | $1.2B | $953.6M |
| Total liabilities and stockholders' equity | $3.0B | $3.5B | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | ||
| Common stock, shares issued (in shares) | 131.1M shares | 124.9M shares | ||
| Common stock, shares outstanding (in shares) | 131.1M shares | 124.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $174.0M | $387.9M | $397.5M | |
| Short-term investments | $1.4B | $1.4B | ||
| Prepaid expenses and other current assets | $66.4M | $40.8M | ||
| Total current assets | $1.6B | $1.8B | ||
| Property and equipment, net | $257.4M | $198.0M | ||
| Operating lease right-of-use assets | $116.0M | $72.1M | ||
| Long-term investments | $881.7M | $1.4B | ||
| Restricted cash | $1.5M | $1.3M | ||
| Other assets | $118.8M | $64.4M | ||
| Total noncurrent assets | $1.4B | $1.7B | ||
| Total assets | $3.0B | $3.5B | ||
| Accounts payable | $70.9M | $48.5M | ||
| Accrued compensation | $23.0M | $20.6M | ||
| Accrued contract manufacturing expenses | $74.7M | $36.2M | ||
| Accrued expenses | $31.1M | $29.1M | ||
| Operating lease liabilities current | $6.1M | $5.9M | ||
| Total current liabilities | $205.8M | $140.2M | ||
| Operating lease liabilities long-term | $111.4M | $65.2M | ||
| Other liabilities | $100.0K | $100.0K | ||
| Total liabilities | $317.2M | $205.5M | ||
| Preferred stock, $0.001 par value 10,000,000 authorized at December 31, 2025 and December 31, 2024; no shares issued and outstanding at December 31, 2025 and December 31, 2024 | $0 | $0 | ||
| Common stock, $0.001 par value 500,000,000 shares authorized at December 31, 2025 and December 31, 2024; 131,058,858 and 124,893,034 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $134.0K | $128.0K | ||
| Additional paid-in capital | $4.8B | $4.7B | ||
| Accumulated other comprehensive income (loss) | $1.6M | -$3.9M | ||
| Accumulated deficit | -$2.2B | -$1.4B | ||
| Total stockholders' equity | $2.7B | $3.3B | $1.2B | $953.6M |
| Total liabilities and stockholders' equity | $3.0B | $3.5B | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | ||
| Common stock, shares issued (in shares) | 131.1M shares | 124.9M shares | ||
| Common stock, shares outstanding (in shares) | 131.1M shares | 124.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$766.6M | -$463.9M | -$402.3M |
| Depreciation and amortization | $16.4M | $7.0M | $3.2M |
| Stock-based compensation expense | $138.8M | $84.8M | $48.8M |
| Amortization of operating lease right-of-use assets | $8.5M | $8.8M | $7.0M |
| Net accretion of discounts on investments | -$14.4M | -$38.7M | -$34.8M |
| Unrealized foreign exchange loss (gain) | -$34.8M | $4.2M | $0 |
| Prepaid expenses and other current assets | -$16.8M | -$5.8M | $17.9M |
| Operating lease right-of-use assets | -$52.4M | -$49.9M | -$16.7M |
| Other assets | -$39.9M | -$26.5M | -$33.0M |
| Operating lease liabilities | $46.4M | $41.9M | $11.3M |
| Accounts payable | $19.9M | $34.6M | $11.2M |
| Accrued compensation | $2.3M | $9.5M | $9.9M |
| Accrued contract manufacturing expenses | $31.1M | -$22.9M | $44.5M |
| Accrued expenses | $6.0M | -$35.7M | $36.3M |
| Net cash used in operating activities | -$655.6M | -$452.6M | -$296.8M |
| Purchases of property and equipment | -$13.7M | -$22.4M | -$16.1M |
| Purchases of manufacturing facility build-out and equipment construction-in-progress | -$43.3M | -$96.7M | -$51.8M |
| Purchases of investments | $1.2B | $3.1B | $1.3B |
| Maturities of investments | $1.5B | $1.1B | $611.9M |
| Sales of investments | $174.7M | $67.0M | $12.6M |
| Net cash provided by (used in) investing activities | $437.4M | -$2.0B | -$773.3M |
| Proceeds from issuance of common stock and pre-funded warrants from follow-on offerings, net of issuance costs | $0 | $2.2B | $545.3M |
| Proceeds from issuance of common stock under at-the-market offering, net of issuance costs | $0 | $195.9M | $90.7M |
| Proceeds from issuance of shares through employee equity incentive plans | $13.0M | $27.1M | $7.6M |
| Taxes paid related to the net share settlement of equity awards | -$11.0M | -$14.3M | -$3.9M |
| Net cash provided by financing activities | $2.0M | $2.4B | $639.8M |
| Effect of exchange rate changes on cash and cash equivalents | $2.4M | $426.0K | -$6.7M |
| Net decrease in cash, cash equivalents and restricted cash | -$213.8M | -$9.4M | -$437.0M |
| Purchases of property and equipment recorded in accounts payable and accrued expenses | $7.5M | $13.2M | $8.5M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Vaxcyte, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2025
- Chief executive officerGrant Pickering Jun 11, 2020 to now11
- PresidentAndrew Guggenhime Apr 6, 2021 to now12
- PresidentGrant Pickering Jun 11, 2020 to Mar 23, 202111
- Chief financial officerAndrew Guggenhime Jun 11, 2020 to now13
- Chief operating officerJim Wassil Jun 11, 2020 to now14
Board members and other officers (22)
- Chief Medical OfficerLuis Jodar Sep 9, 2026 to now15
- OfficerElvia Cowan Jan 4, 2023 to now16
- SVP, Gen Counsel & Corp SecMikhail Eydelman Apr 11, 2022 to Mar 7, 202517
- SVP Cml Mfg & Supply ChainHarpreet S. Dhaliwal Oct 6, 2021 to now18
- VP, ResearchJeff Fairman Jun 11, 2020 to Jan 4, 202319
- SVP Process Dev, ManufacturingPaul Sauer Jun 11, 2020 to Jan 4, 202320
- Board memberJohn Markels Jul 16, 2026 to now21
- Board memberJacks Lee Nov 29, 2023 to now22
- Board memberTeri Loxam Sep 20, 2021 to now23
- Board memberAnne S. Drapeau Sep 24, 2021 to now24
- Board memberCarlos Paya V. Oct 29, 2021 to now25
- Board memberMichael E. Kamarck Oct 29, 2021 to Jun 15, 202326
- Board memberGrant Pickering Jun 11, 2020 to now11
- Board memberHalley E. Gilbert Jun 11, 2020 to now27
- Board memberHeath Lukatch Jun 11, 2020 to now28
- Board memberKurt Von Emster Jun 11, 2020 to Jun 3, 202129
- Board memberMoncef Slaoui Jun 11, 2020 to now30
- Board memberPatrick J. Heron Jun 11, 2020 to Jun 3, 202131
- Board memberPeter Hirth Jun 11, 2020 to Jun 10, 202432
- Board memberRobert Lorne Hopfner Jun 11, 2020 to Jun 3, 202133
- Board memberWilliam J. Newell Jun 11, 2020 to Dec 10, 202034
- General counselJane Wright Mitchell Jun 11, 2020 to Aug 18, 202135
Former names
- SutroVax, Inc.Jul 24, 2015 to Apr 3, 20202
Timeline
Filings
612 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 57 major events, 325 insider forms, 41 large holders, 169 other. The latest 20:
- Oct 9, 20268-K EDGAR
- Oct 8, 2026424B5 EDGAR
- Oct 8, 2026424B5 EDGAR
- Oct 7, 20264 EDGAR
- Oct 7, 20264 EDGAR
- Oct 7, 2026FWP EDGAR
- Oct 6, 2026305B2 EDGAR
- Oct 6, 2026424B5 EDGAR
- Oct 6, 2026424B5 EDGAR
- Oct 5, 2026144 EDGAR
- Oct 5, 2026144 EDGAR
- Oct 5, 20268-K EDGAR
- Oct 2, 20264 EDGAR
- Oct 1, 2026144 EDGAR
- Sep 9, 20264 EDGAR
- Sep 9, 20263 EDGAR
- Sep 9, 2026144 EDGAR
- Sep 9, 20264 EDGAR
- Sep 9, 20264 EDGAR
- Sep 9, 20264 EDGAR
The 612 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 41 such filings since October 2021, the latest 10:
- Aug 11, 2026SCHEDULE 13G/A
- Aug 7, 2026SCHEDULE 13G/A
- Aug 6, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G/A
- May 6, 2026SCHEDULE 13G/A
- Apr 30, 2026SCHEDULE 13G
- Mar 27, 2026SCHEDULE 13G/A
- Feb 17, 2026SCHEDULE 13G/A
- Nov 14, 2025SCHEDULE 13G
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Fmr LLC | 20,852,907 | $1.2B | 0.1% | +4,360,046 |
| Jupiter Topco LLC | 17,965,847 | $1.0B | 0.4% | New |
| BlackRock, Inc. | 12,068,129 | $701.5M | 0.0% | +1,096,313 |
| Ra Capital Management, L.P. | 11,474,599 | $667.0M | 5.8% | No change |
| Wellington Management Group Llp | 7,001,565 | $407.0M | 0.1% | +1,386,968 |
| Vanguard Portfolio Management LLC | 6,593,551 | $383.3M | 0.0% | +314,006 |
| Vanguard Capital Management LLC | 6,348,679 | $369.0M | 0.0% | +81,978 |
| State Street Corp | 5,351,698 | $311.1M | 0.0% | +911,179 |
| Deep Track Capital, LP | 4,300,000 | $250.0M | 3.7% | No change |
| Geode Capital Management, LLC | 3,459,363 | $201.1M | 0.0% | +258,080 |
| Kynam Capital Management, LP | 2,922,335 | $169.9M | 9.4% | No change |
| Westfield Capital Management Co LP | 2,472,428 | $143.7M | 0.5% | −1,173,710 |
| Caligan Partners LP | 2,188,636 | $127.2M | 6.1% | +127,917 |
| Paradigm Biocapital Advisors LP | 2,127,852 | $123.7M | 2.3% | −2,665,168 |
| Bellevue Group AG | 1,971,935 | $114.6M | 2.4% | +781,238 |
| D. E. Shaw & Co., Inc. | 1,901,872 | $110.6M | 0.1% | −963,446 |
| Maverick Capital Ltd | 1,613,242 | $93.8M | 0.8% | +235,504 |
| Charles Schwab Investment Management Inc | 1,464,812 | $85.1M | 0.0% | +60,864 |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,425,470 | $82.9M | 26.9% | +53,045 |
| Eventide Asset Management, LLC | 1,380,219 | $80.2M | 1.1% | +5,927 |
| Goldman Sachs Group Inc | 1,350,760 | $78.5M | 0.0% | +75,724 |
| Northern Trust Corp | 1,280,172 | $74.4M | 0.0% | +135,703 |
| Norges Bank | 1,245,805 | $72.4M | 0.0% | New |
| Jpmorgan Chase & Co | 1,227,346 | $71.2M | 0.0% | +219,032 |
| Dimensional Fund Advisors LP | 1,194,754 | $69.4M | 0.0% | +818,982 |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
9 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Jul 16, 2026 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | +13.7% | Report |
| May 13, 2026 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | +16.3% | Report |
| May 12, 2026 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | +16.3% | Report |
| Apr 28, 2025 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | +58.3% | Report |
| Apr 15, 2025 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | +72.4% | Report |
| Apr 14, 2025 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | +60.6% | Report |
| Mar 5, 2025 | Jefferson ShreveRepublican, House | Sale | $15,001 - $50,000 | +44.0% | Report |
| Dec 12, 2022 | Christopher L. Jacobs, House | Sale | $1,001 - $15,000 | +45.7% | Report |
| Nov 8, 2022 | Christopher L. Jacobs, House | Buy | $1,001 - $15,000 | −56.3% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARVaxcyte, Inc. filings on SEC EDGAR
- 2SEC EDGARVaxcyte, Inc. filings on SEC EDGAR
- 3SEC EDGARVaxcyte, Inc. 10-K for fiscal 2019
- 4SEC EDGARVaxcyte, Inc. 10-K for fiscal 2020
- 5SEC EDGARVaxcyte, Inc. 10-K for fiscal 2021
- 6SEC EDGARVaxcyte, Inc. 10-K for fiscal 2022
- 7SEC EDGARVaxcyte, Inc. 10-K for fiscal 2023
- 8SEC EDGARVaxcyte, Inc. 10-Q for fiscal 2026
- 9SEC EDGARVaxcyte, Inc. 10-Q for fiscal 2026
- 10SEC EDGARVaxcyte, Inc. 10-K for fiscal 2019
- 11
- 12SEC EDGARAndrew Guggenhime, President
- 13
- 14SEC EDGARJim Wassil, Chief operating officer
- 15SEC EDGARLuis Jodar, Chief Medical Officer
- 16SEC EDGARElvia Cowan, Officer
- 17
- 18
- 19SEC EDGARJeff Fairman, VP, Research
- 20
- 21SEC EDGARJohn Markels, Board member
- 22SEC EDGARJacks Lee, Board member
- 23SEC EDGARTeri Loxam, Board member
- 24SEC EDGARAnne S. Drapeau, Board member
- 25SEC EDGARCarlos Paya V., Board member
- 26SEC EDGARMichael E. Kamarck, Board member
- 27SEC EDGARHalley E. Gilbert, Board member
- 28SEC EDGARHeath Lukatch, Board member
- 29SEC EDGARKurt Von Emster, Board member
- 30SEC EDGARMoncef Slaoui, Board member
- 31SEC EDGARPatrick J. Heron, Board member
- 32SEC EDGARPeter Hirth, Board member
- 33SEC EDGARRobert Lorne Hopfner, Board member
- 34SEC EDGARWilliam J. Newell, Board member
- 35
- 36